[
  {
    "title": "High Growth Tech Stocks to Watch in US Market February 2025",
    "published": 1740740897,
    "day_prices": {
      "2025-02-28T14:30:00+00:00": 73.55999755859375,
      "2025-02-28T15:30:00+00:00": 73.08000183105469,
      "2025-02-28T16:30:00+00:00": 72.76000213623047,
      "2025-02-28T17:30:00+00:00": 72.9800033569336,
      "2025-02-28T18:30:00+00:00": 72.77999877929688,
      "2025-02-28T19:30:00+00:00": 72.80000305175781,
      "2025-02-28T20:30:00+00:00": 73.22000122070312
    },
    "sentiment": 0.8186557292938232
  },
  {
    "title": "Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery",
    "published": 1740491624,
    "day_prices": {
      "2025-02-25T14:30:00+00:00": 74.36000061035156,
      "2025-02-25T15:30:00+00:00": 75.68000030517578,
      "2025-02-25T16:30:00+00:00": 74.88929748535156,
      "2025-02-25T17:30:00+00:00": 74.77999877929688,
      "2025-02-25T18:30:00+00:00": 74.95500183105469,
      "2025-02-25T19:30:00+00:00": 74.0,
      "2025-02-25T20:30:00+00:00": 74.63999938964844
    },
    "sentiment": 0.8288907408714294
  },
  {
    "title": "Compass Therapeutics: Good Execution, Major Catalysts Ahead",
    "published": 1740392127,
    "day_prices": {
      "2025-02-24T14:30:00+00:00": 72.19000244140625,
      "2025-02-24T15:30:00+00:00": 72.69999694824219,
      "2025-02-24T16:30:00+00:00": 73.3499984741211,
      "2025-02-24T17:30:00+00:00": 73.30999755859375,
      "2025-02-24T18:30:00+00:00": 73.66000366210938,
      "2025-02-24T19:30:00+00:00": 73.96499633789062,
      "2025-02-24T20:30:00+00:00": 74.02999877929688
    },
    "sentiment": 0.9030687212944031
  },
  {
    "title": "Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration",
    "published": 1740056400,
    "day_prices": {
      "2025-02-20T14:30:00+00:00": 70.26000213623047,
      "2025-02-20T15:30:00+00:00": 70.88140106201172,
      "2025-02-20T16:30:00+00:00": 71.30000305175781,
      "2025-02-20T17:30:00+00:00": 70.58000183105469,
      "2025-02-20T18:30:00+00:00": 70.6500015258789,
      "2025-02-20T19:30:00+00:00": 70.58000183105469,
      "2025-02-20T20:30:00+00:00": 70.98500061035156
    },
    "sentiment": 0.8215861320495605
  },
  {
    "title": "Incyte Stock Sees Relative Strength Rating Rise To 71",
    "published": 1739913360,
    "day_prices": {
      "2025-02-18T14:30:00+00:00": 70.86199951171875,
      "2025-02-18T15:30:00+00:00": 70.88999938964844,
      "2025-02-18T16:30:00+00:00": 70.9800033569336,
      "2025-02-18T17:30:00+00:00": 70.88500213623047,
      "2025-02-18T18:30:00+00:00": 70.68099975585938,
      "2025-02-18T19:30:00+00:00": 70.95999908447266,
      "2025-02-18T20:30:00+00:00": 71.125
    },
    "sentiment": 0.9325262308120728
  },
  {
    "title": "3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value",
    "published": 1739786543,
    "day_prices": {},
    "sentiment": 0.9476976990699768
  },
  {
    "title": "Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade",
    "published": 1739294443,
    "day_prices": {
      "2025-02-11T14:30:00+00:00": 67.5199966430664,
      "2025-02-11T15:30:00+00:00": 66.84500122070312,
      "2025-02-11T16:30:00+00:00": 67.4000015258789,
      "2025-02-11T17:30:00+00:00": 67.0999984741211,
      "2025-02-11T18:30:00+00:00": 66.81500244140625,
      "2025-02-11T19:30:00+00:00": 67.02999877929688,
      "2025-02-11T20:30:00+00:00": 66.81099700927734
    },
    "sentiment": 0.6216502785682678
  },
  {
    "title": "Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags",
    "published": 1739268380,
    "day_prices": {
      "2025-02-11T14:30:00+00:00": 67.5199966430664,
      "2025-02-11T15:30:00+00:00": 66.84500122070312,
      "2025-02-11T16:30:00+00:00": 67.4000015258789,
      "2025-02-11T17:30:00+00:00": 67.0999984741211,
      "2025-02-11T18:30:00+00:00": 66.81500244140625,
      "2025-02-11T19:30:00+00:00": 67.02999877929688,
      "2025-02-11T20:30:00+00:00": 66.81099700927734
    },
    "sentiment": 0.686204195022583
  },
  {
    "title": "Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule",
    "published": 1739257758,
    "day_prices": {
      "2025-02-11T14:30:00+00:00": 67.5199966430664,
      "2025-02-11T15:30:00+00:00": 66.84500122070312,
      "2025-02-11T16:30:00+00:00": 67.4000015258789,
      "2025-02-11T17:30:00+00:00": 67.0999984741211,
      "2025-02-11T18:30:00+00:00": 66.81500244140625,
      "2025-02-11T19:30:00+00:00": 67.02999877929688,
      "2025-02-11T20:30:00+00:00": 66.81099700927734
    },
    "sentiment": 0.8586742877960205
  },
  {
    "title": "Q4 2024 Incyte Corp Earnings Call",
    "published": 1739248092,
    "day_prices": {
      "2025-02-11T14:30:00+00:00": 67.5199966430664,
      "2025-02-11T15:30:00+00:00": 66.84500122070312,
      "2025-02-11T16:30:00+00:00": 67.4000015258789,
      "2025-02-11T17:30:00+00:00": 67.0999984741211,
      "2025-02-11T18:30:00+00:00": 66.81500244140625,
      "2025-02-11T19:30:00+00:00": 67.02999877929688,
      "2025-02-11T20:30:00+00:00": 66.81099700927734
    },
    "sentiment": 0.8186153173446655
  },
  {
    "title": "Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript",
    "published": 1739188344,
    "day_prices": {
      "2025-02-10T14:30:00+00:00": 73.37999725341797,
      "2025-02-10T15:30:00+00:00": 69.58999633789062,
      "2025-02-10T16:30:00+00:00": 69.86000061035156,
      "2025-02-10T17:30:00+00:00": 69.87999725341797,
      "2025-02-10T18:30:00+00:00": 69.31999969482422,
      "2025-02-10T19:30:00+00:00": 69.4800033569336,
      "2025-02-10T20:30:00+00:00": 68.51000213623047
    },
    "sentiment": 0.9270460605621338
  },
  {
    "title": "Incyte Corp. stock underperforms Friday when compared to competitors",
    "published": 1738948500,
    "day_prices": {
      "2025-02-07T14:30:00+00:00": 75.37000274658203,
      "2025-02-07T15:30:00+00:00": 75.3499984741211,
      "2025-02-07T16:30:00+00:00": 74.93499755859375,
      "2025-02-07T17:30:00+00:00": 74.73999786376953,
      "2025-02-07T18:30:00+00:00": 74.69000244140625,
      "2025-02-07T19:30:00+00:00": 74.47000122070312,
      "2025-02-07T20:30:00+00:00": 74.5
    },
    "sentiment": 0.915343701839447
  },
  {
    "title": "Knight Therapeutics Announces Launch of Minjuvi\u00ae (tafasitamab) in Mexico",
    "published": 1742988600,
    "day_prices": {
      "2025-03-26T13:30:00+00:00": 62.06999969482422,
      "2025-03-26T14:30:00+00:00": 62.56999969482422,
      "2025-03-26T15:30:00+00:00": 61.58000183105469,
      "2025-03-26T16:30:00+00:00": 61.040000915527344,
      "2025-03-26T17:30:00+00:00": 61.099998474121094,
      "2025-03-26T18:30:00+00:00": 61.17499923706055,
      "2025-03-26T19:30:00+00:00": 61.150001525878906
    },
    "sentiment": 0.5715783834457397
  },
  {
    "title": "What Moved Markets This Week",
    "published": 1742625968,
    "day_prices": {},
    "sentiment": 0.8853694200515747
  },
  {
    "title": "Why Incyte Stock Was Tanking This Week",
    "published": 1742572579,
    "day_prices": {
      "2025-03-21T13:30:00+00:00": 60.439998626708984,
      "2025-03-21T14:30:00+00:00": 61.22999954223633,
      "2025-03-21T15:30:00+00:00": 61.209999084472656,
      "2025-03-21T16:30:00+00:00": 61.90999984741211,
      "2025-03-21T17:30:00+00:00": 61.9900016784668,
      "2025-03-21T18:30:00+00:00": 62.1150016784668,
      "2025-03-21T19:30:00+00:00": 62.01499938964844
    },
    "sentiment": 0.8608781099319458
  },
  {
    "title": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
    "published": 1742546760,
    "day_prices": {
      "2025-03-21T13:30:00+00:00": 60.439998626708984,
      "2025-03-21T14:30:00+00:00": 61.22999954223633,
      "2025-03-21T15:30:00+00:00": 61.209999084472656,
      "2025-03-21T16:30:00+00:00": 61.90999984741211,
      "2025-03-21T17:30:00+00:00": 61.9900016784668,
      "2025-03-21T18:30:00+00:00": 62.1150016784668,
      "2025-03-21T19:30:00+00:00": 62.01499938964844
    },
    "sentiment": 0.9428064227104187
  },
  {
    "title": "Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More",
    "published": 1742489100,
    "day_prices": {
      "2025-03-20T13:30:00+00:00": 60.2599983215332,
      "2025-03-20T14:30:00+00:00": 60.79499816894531,
      "2025-03-20T15:30:00+00:00": 60.630001068115234,
      "2025-03-20T16:30:00+00:00": 60.467498779296875,
      "2025-03-20T17:30:00+00:00": 60.41999816894531,
      "2025-03-20T18:30:00+00:00": 60.5099983215332,
      "2025-03-20T19:30:00+00:00": 60.470001220703125
    },
    "sentiment": 0.6814180612564087
  },
  {
    "title": "Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack",
    "published": 1742461785,
    "day_prices": {
      "2025-03-20T13:30:00+00:00": 60.2599983215332,
      "2025-03-20T14:30:00+00:00": 60.79499816894531,
      "2025-03-20T15:30:00+00:00": 60.630001068115234,
      "2025-03-20T16:30:00+00:00": 60.467498779296875,
      "2025-03-20T17:30:00+00:00": 60.41999816894531,
      "2025-03-20T18:30:00+00:00": 60.5099983215332,
      "2025-03-20T19:30:00+00:00": 60.470001220703125
    },
    "sentiment": 0.6199098825454712
  },
  {
    "title": "INCY Stock Down on Disappointing Skin Disease Study Data",
    "published": 1742324400,
    "day_prices": {
      "2025-03-18T13:30:00+00:00": 61.029998779296875,
      "2025-03-18T14:30:00+00:00": 59.86000061035156,
      "2025-03-18T15:30:00+00:00": 60.400001525878906,
      "2025-03-18T16:30:00+00:00": 60.5,
      "2025-03-18T17:30:00+00:00": 60.28499984741211,
      "2025-03-18T18:30:00+00:00": 60.31999969482422,
      "2025-03-18T19:30:00+00:00": 60.35499954223633
    },
    "sentiment": 0.9624051451683044
  },
  {
    "title": "Stoke CEO exits; Medicare drug price talks advance",
    "published": 1742299500,
    "day_prices": {
      "2025-03-18T13:30:00+00:00": 61.029998779296875,
      "2025-03-18T14:30:00+00:00": 59.86000061035156,
      "2025-03-18T15:30:00+00:00": 60.400001525878906,
      "2025-03-18T16:30:00+00:00": 60.5,
      "2025-03-18T17:30:00+00:00": 60.28499984741211,
      "2025-03-18T18:30:00+00:00": 60.31999969482422,
      "2025-03-18T19:30:00+00:00": 60.35499954223633
    },
    "sentiment": 0.8942402005195618
  },
  {
    "title": "Why Organon Is A Top Pick For Income Investors",
    "published": 1742252303,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.9111111164093018
  },
  {
    "title": "S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision",
    "published": 1742243527,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.6866774559020996
  },
  {
    "title": "Oil pressures, Robinhood, Incyte: Market Minute",
    "published": 1742234964,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.9220467805862427
  },
  {
    "title": "Why Incyte (INCY) Stock Is Nosediving",
    "published": 1742233926,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.7528941631317139
  },
  {
    "title": "Incyte Corp. stock underperforms Monday when compared to competitors",
    "published": 1742229000,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.9303669333457947
  },
  {
    "title": "Top Stock Movers Now: Intel, Netflix, Incyte, and More",
    "published": 1742227236,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.9043291807174683
  },
  {
    "title": "S&P 500 Futures Fall in Premarket Trading; Incyte, Affirm Holdings Lag",
    "published": 1742196600,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.9658000469207764
  },
  {
    "title": "Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa",
    "published": 1742196060,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 60.0,
      "2025-03-17T14:30:00+00:00": 61.130001068115234,
      "2025-03-17T15:30:00+00:00": 60.93000030517578,
      "2025-03-17T16:30:00+00:00": 61.189998626708984,
      "2025-03-17T17:30:00+00:00": 63.029998779296875,
      "2025-03-17T18:30:00+00:00": 62.900001525878906,
      "2025-03-17T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.9198789596557617
  },
  {
    "title": "Tracking Baker Brothers Portfolio - Q4 2024 Update",
    "published": 1741823776,
    "day_prices": {
      "2025-03-12T13:30:00+00:00": 67.8499984741211,
      "2025-03-12T14:30:00+00:00": 67.0824966430664,
      "2025-03-12T15:30:00+00:00": 67.45220184326172,
      "2025-03-12T16:30:00+00:00": 67.69000244140625,
      "2025-03-12T17:30:00+00:00": 68.01000213623047,
      "2025-03-12T18:30:00+00:00": 67.69000244140625,
      "2025-03-12T19:30:00+00:00": 67.625
    },
    "sentiment": 0.9427753686904907
  },
  {
    "title": "Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss",
    "published": 1741697328,
    "day_prices": {
      "2025-03-11T13:30:00+00:00": 70.9800033569336,
      "2025-03-11T14:30:00+00:00": 68.50499725341797,
      "2025-03-11T15:30:00+00:00": 68.43499755859375,
      "2025-03-11T16:30:00+00:00": 68.01000213623047,
      "2025-03-11T17:30:00+00:00": 67.5999984741211,
      "2025-03-11T18:30:00+00:00": 68.19000244140625,
      "2025-03-11T19:30:00+00:00": 68.30000305175781
    },
    "sentiment": 0.9481591582298279
  },
  {
    "title": "INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies",
    "published": 1741618320,
    "day_prices": {
      "2025-03-10T13:30:00+00:00": 69.94000244140625,
      "2025-03-10T14:30:00+00:00": 70.33999633789062,
      "2025-03-10T15:30:00+00:00": 71.0999984741211,
      "2025-03-10T16:30:00+00:00": 71.54499816894531,
      "2025-03-10T17:30:00+00:00": 71.44000244140625,
      "2025-03-10T18:30:00+00:00": 71.06999969482422,
      "2025-03-10T19:30:00+00:00": 71.29000091552734
    },
    "sentiment": 0.9548254013061523
  },
  {
    "title": "Incyte Reports Inducement Grants under Nasdaq Listing Rule 5635(4)",
    "published": 1741610290,
    "day_prices": {
      "2025-03-10T13:30:00+00:00": 69.94000244140625,
      "2025-03-10T14:30:00+00:00": 70.33999633789062,
      "2025-03-10T15:30:00+00:00": 71.0999984741211,
      "2025-03-10T16:30:00+00:00": 71.54499816894531,
      "2025-03-10T17:30:00+00:00": 71.44000244140625,
      "2025-03-10T18:30:00+00:00": 71.06999969482422,
      "2025-03-10T19:30:00+00:00": 71.29000091552734
    },
    "sentiment": 0.9385528564453125
  },
  {
    "title": "Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura\u00ae) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting",
    "published": 1741442460,
    "day_prices": {},
    "sentiment": 0.5486050844192505
  },
  {
    "title": "Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
    "published": 1741383000,
    "day_prices": {
      "2025-03-07T14:30:00+00:00": 69.45999908447266,
      "2025-03-07T15:30:00+00:00": 70.58999633789062,
      "2025-03-07T16:30:00+00:00": 71.0999984741211,
      "2025-03-07T17:30:00+00:00": 71.19000244140625,
      "2025-03-07T18:30:00+00:00": 72.36009979248047,
      "2025-03-07T19:30:00+00:00": 72.0199966430664,
      "2025-03-07T20:30:00+00:00": 71.54000091552734
    },
    "sentiment": 0.9344679117202759
  },
  {
    "title": "Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?",
    "published": 1740857461,
    "day_prices": {},
    "sentiment": 0.8963753581047058
  }
]